Antagonic effect of ghrelin and LEAP-2 on hepatic stellate cell activation and liver fibrosis in obesity-associated NAFLD.
Silvia EzquerroCarlota TueroSara BecerrilVíctor ValentíRafael MoncadaManuel F LandechoVictoria CatalánJavier Gómez-AmbrosiFátima MochaCamilo SilvaKaren Piper HanleyJavier EscaladaGema FrühbeckAmaia RodríguezPublished in: European journal of endocrinology (2023)
Ghrelin is an anti-fibrogenic factor blocking HSC activation induced by the most potent fibrogenic cytokine, TGF-β1, and LEAP-2. The imbalance between acylated ghrelin and ghrelin receptor antagonist LEAP-2 might contribute to maintain liver fibrosis in patients with obesity and NAFLD.